Vericel Corp Ord

Yahoo Finance • 2 days ago

Exploring Three High Growth Tech Stocks In The US Market

In the last week, the United States market has stayed flat, but over the past 12 months, it has risen by 29%, with earnings expected to grow by 16% per annum in the coming years. In this context of robust growth expectations, identifying h... Full story

Yahoo Finance • 29 days ago

Vericel secures $197M BARDA deal, boosting NexoBrid supply plans

* Vericel (VCEL [https://seekingalpha.com/symbol/VCEL]) secured a 10-year contract [https://seekingalpha.com/pr/20461630-vericel-announces-barda-award-valued-at-up-to-197-million-for-procurement-and-advanced] worth up to $197M from the U... Full story

Yahoo Finance • 2 months ago

Vericel Corporation (VCEL) Secures FDA Approval for Commercial Manufacturing of MACI

Vericel Corporation (NASDAQ:VCEL) is one of the Best Small-Cap Growth Stocks to Buy According to Hedge Funds. On March 4, Vericel Corporation (NASDAQ:VCEL) announced securing a major win from the FDA. The company announced receiving FDA a... Full story

Yahoo Finance • 2 months ago

Vericel Announces FDA Approval of New State-of-the-Art Advanced Therapy Manufacturing Facility

Vericel Corporation Company Achieves Significant Regulatory and Operational Milestone Substantially Increases Manufacturing Capacity to Support Long-Term Growth Enables Potential MACI Commercialization Outside of the U.S. CAMBRIDGE, Ma... Full story

Yahoo Finance • 2 months ago

Vericel to Present at Multiple Upcoming Investor Conferences

CAMBRIDGE, Mass., March 03, 2026 (GLOBE NEWSWIRE) -- Vericel Corporation (NASDAQ:VCEL), a leader in advanced therapies for the sports medicine and severe burn care markets, today announced that the Company will present at the following i... Full story

Yahoo Finance • 2 months ago

Vericel Reports Fourth Quarter and Full-Year 2025 Financial Results

Total Revenue of $276.3 Million, with MACI Revenue Growth of 21% to $239.5 Million Net Income Growth of 59% to $16.5 Million Fourth Quarter Total Revenue and MACI Revenue Growth of 23% Record Fourth Quarter Gross Margin of 79% and Adjus... Full story

Yahoo Finance • 3 months ago

Tissue and Regenerative Engineering Market Company, Government & Public Sector Funding Data

Precedence Research Precedence Research, a leading strategic research firm, presents an in-depth analysis of the Tissue and Regenerative Engineering market, highlighting key company performance, product focus, and government funding initi... Full story

Yahoo Finance • 4 months ago

Truist Slashes PT on Vericel Corporation (VCEL) to $45 From $50

Vericel Corporation (NASDAQ:VCEL) is one of the best small cap stocks to buy with huge upside potential. Truist analyst Richard Newitter slashed the price target on Vericel Corporation (NASDAQ:VCEL) to $45 from $50 on December 18, reaffirm... Full story

Yahoo Finance • 6 months ago

Vericel to Present at the Stephens Annual Investment Conference on Thursday, November 20, 2025

CAMBRIDGE, Mass., Nov. 14, 2025 (GLOBE NEWSWIRE) -- Vericel Corporation (NASDAQ:VCEL), a leader in advanced therapies for the sports medicine and severe burn care markets, today announced that the Company will participate in a fireside c... Full story

Yahoo Finance • 6 months ago

Vericel beats top-line and bottom-line estimates; reaffirms FY25 outlook

* Vericel press release [https://seekingalpha.com/pr/20296540-vericel-reports-third-quarter-2025-financial-results] (VCEL [https://seekingalpha.com/symbol/VCEL]): Q3 GAAP EPS of $0.10 beats by $0.11. * Revenue of $67.5M (+16.6% Y/Y) be... Full story

Yahoo Finance • 6 months ago

Vericel Reports Third Quarter 2025 Financial Results

Record Third Quarter Total Revenue of $67.5 Million MACI Revenue Growth of 25% to $55.7 Million Net Income of $5.1 Million and Adjusted EBITDA Margin of 25% Record Third Quarter Operating Cash Flow of $22.1 Million More than 800 MACI A... Full story

Yahoo Finance • 6 months ago

Exploring High Growth Tech Stocks In The US Market

As the U.S. stock market experiences a surge, with key indices like the Nasdaq and S&P 500 posting significant gains, investors are closely monitoring high-growth tech stocks that continue to capture attention amid economic uncertainties s... Full story

Yahoo Finance • 7 months ago

US High Growth Tech Stocks to Watch for Potential Expansion

As the United States stock market continues to reach new heights, with major indices like the S&P 500 and Nasdaq Composite posting consecutive weeks of gains, investors are paying close attention to high-growth sectors such as technology.... Full story

Yahoo Finance • 8 months ago

Vericel to Present at the Wells Fargo Healthcare Conference on Thursday, September 4, 2025

CAMBRIDGE, Mass., Aug. 28, 2025 (GLOBE NEWSWIRE) -- Vericel Corporation (NASDAQ:VCEL), a leader in advanced therapies for the sports medicine and severe burn care markets, today announced that the Company will participate in a fireside c... Full story

Yahoo Finance • 8 months ago

Velo3D stock soars after participating in U.S. Army funded initiative

Investing.com -- Velo3D, Inc. (NASDAQ:VELO) stock surged 31% after the company announced its participation in a U.S. Army-funded initiative to advance high-throughput aluminum manufacturing for defense applications. The additive manufactu... Full story

Yahoo Finance • 9 months ago

Vericel Corp (NASDAQ: VCEL) Posts Mixed Q2 2025 Results with Revenue Miss and EPS Beat

VERICEL CORP (NASDAQ: VCEL [https://www.chartmill.com/stock/quote/VCEL]) REPORTS MIXED Q2 2025 RESULTS AS REVENUE MISSES ESTIMATES, EPS BEATS Vericel Corp released its second-quarter 2025 financial results, revealing a mixed performance r... Full story

Yahoo Finance • 9 months ago

Vericel GAAP EPS of -$0.01 beats by $0.02, revenue of $63.24M misses by $1.25M

* Vericel press release [https://seekingalpha.com/pr/20184663-vericel-reports-second-quarter-2025-financial-results] (NASDAQ:VCEL [https://seekingalpha.com/symbol/VCEL]): Q2 GAAP EPS of -$0.01 beats by $0.02. * Revenue of $63.24M (+20.... Full story

Yahoo Finance • 9 months ago

Vericel Reports Second Quarter 2025 Financial Results

Total Revenue Growth of 20% to $63.2 Million, with MACI Revenue Growth of 21% to $53.5 Million Gross Margin Increased More than 400 Basis Points to 74% Adjusted EBITDA Growth of 112% to $13.4 Million, with Adjusted EBITDA Margin Increase... Full story

Yahoo Finance • 9 months ago

Vericel to Report Second-Quarter 2025 Financial Results on July 31, 2025

CAMBRIDGE, Mass., July 17, 2025 (GLOBE NEWSWIRE) -- Vericel Corporation (NASDAQ:VCEL), a leader in advanced therapies for the sports medicine and severe burn care markets, today announced that the Company will report its second-quarter 2... Full story

Yahoo Finance • 10 months ago

Vericel stock hits 52-week low at $37.38 amid market challenges

Vericel (NASDAQ:VCEL) Corp’s stock has reached a new 52-week low, trading at $37.38. This marks a significant downturn for the company, which has seen its stock value decrease by 28.23% over the past year. Despite the decline, InvestingPro... Full story